Agios Pharmaceuticals, Inc.
LSE: 0HB0.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Brian Goff
- Employees
- 486
- Headquarters
- Cambridge, United States
- IPO year
- 2018
- Market cap
- $1.6B
- Website
- https://www.agios.com
Loading 0HB0…
Loading profile data…Frequently asked questions about 0HB0
What does Agios Pharmaceuticals, Inc. (0HB0.L) do?
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and...
Where does 0HB0.L trade?
Agios Pharmaceuticals, Inc. (0HB0.L) trades on the London Stock Exchange.
What sector is 0HB0.L in?
Agios Pharmaceuticals, Inc. (0HB0.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Agios Pharmaceuticals, Inc.?
Brian Goff is the chief executive officer of Agios Pharmaceuticals, Inc. (0HB0.L).
Where is Agios Pharmaceuticals, Inc. headquartered?
Agios Pharmaceuticals, Inc. is headquartered in United States.
Does 0HB0.L pay a dividend?
Agios Pharmaceuticals, Inc. (0HB0.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0HB0.L go public?
Agios Pharmaceuticals, Inc. (0HB0.L) completed its initial public offering in 2018.